All relevant data is presented in this work. Data protection laws for this study with patient data acquired outside of our institution result in ethical and legal restrictions that do not allow us to publically store all raw imaging data. Contact person for readers regarding the availability of the data is Stefan Delorme (<s.delorme@dkfz.de>); computational data of the FROC model will be available upon request to all interested researchers as far as ethical and legal restrictions are not violated.

Introduction {#sec005}
============

Breast cancer screening programs have been established in many countries in order to reduce the burden of breast cancer in the female population \[[@pone.0176077.ref001]--[@pone.0176077.ref003]\]. While substantial evidence has been provided regarding the benefit of these programs using X-ray mammography as the screening tool, the high rate of false positive findings triggering unnecessary invasive biopsies and potential overdiagnosis have repeatedly been criticized \[[@pone.0176077.ref002], [@pone.0176077.ref004]\].

Current reports from organized, quality-assured breast cancer screening programs report a substantial false-positive rate of about 50% in invasive biopsies \[[@pone.0176077.ref005]\]. Alternative or additive imaging modalities to address this issue have therefore been introduced and are currently being investigated regarding the benefit in a screening environment \[[@pone.0176077.ref006], [@pone.0176077.ref007]\]. Amongst them, magnetic resonance imaging (MRI) has been a promising method, since abbreviated protocols might allow the use in a screening environment and provide a high sensitivity for detecting malignancy exceeding that of X-ray mammography \[[@pone.0176077.ref007]\].

In addition to contrast enhanced protocols, abbreviated unenhanced protocols omitting contrast agent administration have been subject of different studies with promising results regarding the differentiation between malignant and benign breast lesions \[[@pone.0176077.ref008]--[@pone.0176077.ref011]\]. Besides shortening examination times, another aspect of unenhanced, abbreviated breast MRI protocols represent recent reports on gadolinium deposition in the human brain after repetitive intravenous application with unclear clinical relevance \[[@pone.0176077.ref012], [@pone.0176077.ref013]\].

One sequence of increasing interest in breast MRI protocols is the diffusion weighted imaging (DWI) sequence \[[@pone.0176077.ref014]--[@pone.0176077.ref016]\], which is thought to visualize the free Brownian water motion \[[@pone.0176077.ref015], [@pone.0176077.ref017]--[@pone.0176077.ref019]\]. Highly packed cell conglomerates restrict water diffusion thus leading to signal intensity changes on diffusion weighted images.

DWI images are commonly used to calculate apparent diffusion coefficient (*D*~app~) maps. Those maps allow quantifying diffusion restriction, but the clinical acceptance is limited related to the overlap between malignant and benign lesions. Other diffusion models have therefore been suggested aiming to improve the differentiation between tissue structures, e.g. in order to represent the tissue heterogeneity. Increased tissue heterogeneity can be assumed in many malignant entities and might be as well of interest in breast imaging. Malignant cell conglomerates might demonstrate an increased heterogeneity as compared to benign lesions since breast cancer cells have been described as morphologically highly variable \[[@pone.0176077.ref020]\]. One of the diffusion models aiming to produce values that are thought to be related to tissue heterogeneity is the fractional order calculus model (FROC) \[[@pone.0176077.ref021]--[@pone.0176077.ref025]\]. Using the FROC measures *β*~FROC~, *D*~FROC~ and *μ*~FROC~ has recently been proposed to contribute to the differentiation of brain tumors exceeding a conventionally calculated apparent diffusion coefficient *D*~app~ \[[@pone.0176077.ref021]\].

Therefore this study aimed at investigating whether the previously proposed new FROC derived parameters *β*~FROC~, *D*~FROC~ and *μ*~FROC~ as a measure of tissue heterogeneity might be also of diagnostic value in breast imaging in order to differentiate between malignant and benign lesions using unenhanced breast MRI as compared to the apparent diffusion coefficient (*D*~app~).

Materials and methods {#sec006}
=====================

Patients {#sec007}
--------

This study was conducted as a retrospective subgroup analysis of an ongoing larger prospective multicenter study on DWI in breast imaging with written informed consent and institutional and governmental review board approval. Preliminary results of patients in one study site that received acquisition of a vendor specific DWI sequence (Diffusion Weighted Imaging With Background Suppression, DWIBS) have been published regarding the usability of different visual radiologists´ reading strategies of an abbreviated breast MRI protocol for breast cancer screening work-up and in regards to so called radiomics analyses of the DWI ()\[[@pone.0176077.ref009], [@pone.0176077.ref026]--[@pone.0176077.ref028]\]. Mathematical analysis of the FROC derived parameters *β*~FROC~, *D*~FROC~ and *μ*~FROC~ as evaluated in this study here have not been part of these previously published analyses and the patients described originate from a different study site. Since all patients belong to one multicenter study concept, however, data, principles and background of the methods described here may partially overlap to the previous reports \[[@pone.0176077.ref009], [@pone.0176077.ref026]--[@pone.0176077.ref028]\].

51 patients (mean age 58 years; SD ± 6.2) were analyzed out of the recruitment period between May 2015 and February 2016. Inclusion criteria were: female participants of the national breast cancer screening program with a BIRADS 4/5 lesion in the primary screening X-ray mammogram; a regular subsequent screening work-up process that included clinical, ultrasonographic (US) and, if necessary, repeat mammography examinations; final indication for biopsy in concordance to the screening guidelines and the Breast Imaging Reporting and Data System (BI-RADS) category 4 or 5.

MR imaging {#sec008}
----------

Patients participating in the study received a MR examination prior biopsy as previously described \[[@pone.0176077.ref026]\]. The MR examination consisted of a full diagnostic protocol including unenhanced morphologic sequences (T1-weighted, T2-weighted), contrast enhanced sequences (0.1 mmol Gadobenate Dimeglumine (Multihance; Bracco, Mailand, Italy) per kilogram of body weight) and diffusion weighted sequences with details described in [Table 1](#pone.0176077.t001){ref-type="table"}. MR imaging examinations were performed using a 1.5-T MR imaging unit (Aera, Siemens, Erlangen, Germany) with a dedicated 18-channel breast coil. Participants were placed in prone position with the breasts not compressed but softly fixed using foamed material.

10.1371/journal.pone.0176077.t001

###### Sequence parameters.
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  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                  Slice thickness\   FOV\        Voxel Size   Orientation   TE (ms)   TR (ms)   b-value s/mm^2^                                 Phase enconding direction   Additional feature
                  (mm)               (mm x mm)                                                                                                                              
  --------------- ------------------ ----------- ------------ ------------- --------- --------- ----------------------------------------------- --------------------------- --------------------------------------------------------------------------
  **Localizer**                                                                                                                                                             

  **T1w TSE**\    3                  384x384     1x1.3        Coronal       8         886       \-                                              RL                          Grappa x2

  **T2w fs**      3                  263x350\    0.9x0.6      Transverse    82        8490      \-                                              RL                          "TIRM"

  **T2w TSE**     3                  263x350\    0.9x0.6      Transverse    120       6710      \-                                              RL                          Grappa x2

  **DWI**         3                  480x240\    2.5 x 2.5    Transverse    80        11700     b~1~ = 0, b~2~ = 100, b~3~ = 750, b~4~ = 1500   AP\                         SPAIR, Parallel imaging: Grappa x2, EPI-factor 96; Number of averages: 2

  **T1w DCE**     1                  350x263\    1.0x0.6\     Transverse    4.6       11        \-                                              RL                          6 dynamic pre-/post-contrast series, each 1.23 min; Grappa x2\

  **T1w TSE**     2                  156/343\    1.2/0.8\     Transverse\   4.6       30        \-                                              AP                          3D
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: TSE = Turbo Spin Echo, FOV = Field of View, TE = Echo Time, TR = Repetition Time, RL = Left-Right, AP = Anterior-Posterior, SPAIR = Spectral Attenuated Inversion Recovery; TIRM = Turbo Inversion Recovery Magnitude, DCE = dynamic contrast-enhanced; GRAPPA = generalized autocalibrating partially parallel acquisition, mm = millimeter.

The DWI sequence was run with multiple b-values to allow for further fitting strategies. The upper limit of the b-values was chosen in order to provide a high specificity for displaying suspicious lesions while preserving sufficient suppression of other tissues. The DWI sequence was acquired prior contrast agent administration to avoid a potential influence of gadolinium on the DWI signal. The following parameters were applied: Echo Time (ms) 80; Repetition Time (ms) 1170; b-values 0, 100, 750, 1500 s/mm^2^; Spectral attenuated Inversion Recovery (SPAIR) fat suppression; Parallel Imaging, EPI-factor 96; separation between two diffusion gradient lobes 35.1 ms; duration of each diffusion gradient 14.1 ms; field of view 480 x 240 mm^2^; slice thickness 3 mm; imaging time 6:44 minutes; 50 slices.

Image analysis {#sec009}
--------------

For imaging analysis, a previously published methodology for FROC analyses in brain tumors for the analysis of breast lesions was adapted \[[@pone.0176077.ref021], [@pone.0176077.ref022]\].

Regions of interest (ROIs) were drawn at the inner border of the lesion that was indicated for biopsy by using the images acquired with *b* = 1500 s/mm^2^. ROIs were placed slice by slice for the respective lesion creating a 3-dimensional volume for each lesion. Lesions were correlated to the X-ray mammogram using a visual correlation by two radiologists (\*blinded\*, \<1 year experience, \*blinded\*, \>5 years experience) in consensus, since correlation by means of invasive markers (clips) was not available.

The FROC model was used to calculate the voxel intensity within a diffusion weighted image as given by the equation $$S = S_{0}{\exp\ \left( {- D_{FROC}\mu_{FROC}^{2({\beta_{FROC} - 1})}\left( {\gamma G\delta} \right)^{2\beta_{FROC}}\left( {\Delta - \frac{2\beta - 1}{2\beta + 1}\delta} \right)} \right)}$$

In this equation, *S*~0~ is the signal intensity as given without diffusion weighting, *D*~FROC~ is the FROC diffusion coefficient, *β*~FROC~ is the fractional order derivative in space, *G* is the diffusion gradient amplitude, *δ* is the diffusion gradient pulse width, Δ is the gradient lobe separation \[[@pone.0176077.ref021]--[@pone.0176077.ref023]\].

The apparent diffusion coefficient *D*~app~ was calculated using a monoexponential fit using images acquired with *b* = 0 s/mm^2^, *b* = 100 s/mm^2^ and *b* = 750 s/mm. The fitting of the FROC parameters was performed in adaption to previous studies \[[@pone.0176077.ref021], [@pone.0176077.ref022]\] in a voxel by voxel manner using the Levenberg-Marquardt non-linear fitting method \[[@pone.0176077.ref021]\]. The initial *D*~FROC~ value was obtained from images at b-values ≤750 s/mm^2^ using the monoexponential fit. The initial *β*~FROC~ value was set to 0.5. Using these initial values for *D*~FROC~ and *β*~FROC~, the initial *μ*~FROC~ value was determined by fitting [Eq 1](#pone.0176077.e001){ref-type="disp-formula"} with *μ*~FROC~ being the only free variable. Afterwards, FROC parameters *β*~FROC~, *D*~FROC~ and *μ*~FROC~ were calculated with the Levenberg-Marquardt algorithm using the b-values 100, 750, and 1500 s/mm^2^. *S*~0~ was not fitted but set to the signal value at *b* = 0. This fitting approach is reproducible, i.e. performing this procedure twice yields identical results. However, *D*~FROC~ and *μ*~FROC~ are strongly coupled in [Eq 1](#pone.0176077.e001){ref-type="disp-formula"}, so that the obtained values of these parameters were found to depend on their initial values. This limitation is described in more detail in the Supplemental Information.

The choice of b-values in this study allowed for an additional evaluation using the IVIM model \[[@pone.0176077.ref029]\]. IVIM parameters were calculated using using all b-values fitting with the Levenberg-Marquardt algorithm: $$S = S_{0}\left\lbrack {f_{IVIM}exp\left( {- bD_{IVIM}^{*}} \right) + \left( {1 - f_{IVIM}} \right){\exp\left( {- bD_{IVIM}} \right)}} \right\rbrack,$$ where $D_{IVIM}^{*}$ is the pseudo diffusion coefficient and *f*~IVIM~ is the perfusion fraction. $D_{IVIM}^{*}$ was fitted, but not used for further analysis due to the observed large fit instability.

Lesion size was measured using T2-weighted images with the maximal lesion diameter being measured in axial orientation by one reader.

To analyze a potential influence of lesion size, lesions were separated into two groups (below and above 10 mm maximal in plane diameter) thus defining a clinical threshold. The quantitative FROC model analysis was performed individually for these two groups.

All image processing was performed using software code developed with Matlab (MathWorks, Natick, Massachusetts).

Histopathology {#sec010}
--------------

All patients participating this study underwent core-needle biopsy of the suspicious lesion as indicated in the screening clarification process. Histopathological analyses served as the standard of reference regarding the classification in benign or malignant lesions.

Statistical analysis {#sec011}
--------------------

For each patient, the values of the parameters (*D*~app~, *β*~FROC~, *D*~FROC~ and *μ*~FROC~) and of the IVIM parameters were calculated for each voxel within the Volume of Interest. For both, the malignant and the benign lesions, mean and 25% - 75% percentile were calculated and compared using Mann-Whitney U test after normality testing with Shapiro-Wilk test failed.

Receiving operating characteristics (ROC) were calculated in order to evaluate the area under the ROC curve (AUC) and to assess the performance of each individual parameter.

Significant differences were considered for a p-value \<0.05. Statistics were calculated using SigmaPlot (Systat Software; Erkrath, Germany).

Results {#sec012}
=======

Cancer burden and histopathological characteristics within the study population {#sec013}
-------------------------------------------------------------------------------

Of the 51 patients in the study, 29 (58%) had a malignancy. Of the malignant lesions, most lesions were described as invasive ductal carcinoma (IDC; n = 26; 89.6%), two lesions were invasive lobular carcinoma (ILC; 6.8%) and one lesion was a ductal carcinoma in situ (DCIS; 3.4%). Of the benign lesions, six lesions were fibroadenoma (27.3%), five lesions were revealed as fibrosis (22.7%), three lesions were papilloma (13.6%), two lesions each were usual ductal hyperplasia (UDH, 9.1%), compacted breast tissue (9.1%) and fibrocystic mastopathy (9.1%), and one lesion each was fat tissue (4.5%) and granulomatous lymphadenitis (4.5%). (see [Table 2](#pone.0176077.t002){ref-type="table"} for details).

10.1371/journal.pone.0176077.t002

###### Type and distribution of lesions within the study population.
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  ----------------------------------------------------------------------------------------------
                                                          Number     Percentage
  ------------------- ----------------------------------- ---------- ---------------------------
  **Benign**          Granulomatous lymphadenitis         n = 1      4.%

                      Compacted breast tissue             n = 2      9.1%

  ***(n = 22)***      Ductal hyperplasia                  n = 2      9.1%

  ***(52%)***         Fibroadenoma                        n = 6      27.3%

                      Fibrosis                            n = 5      22.7%

                      Fibrocystic mastopathia             n = 2      9.1%

                      Papilloma                           n = 3      13.6%

                      Fat tissue                          n = 1      4.5%

  **Malignant**                                                      

  ***n = 29***        Invasive ductal carcinoma (IDC)\*   n = 26     89.6%

  ***(58%)***         carcinoma in situ (DCIS)            n = 1      3.4%

                      Invasive lobular carcinoma          n = 2      6.8%

  ***Lesion Size***                                       **Mean**   **SD**

                      **Benign**                          11.54 mm   4.03 mm\
                                                                     (range 4.9--21.7)

                      **Malignant**                       12.56 mm   5.17 mm (range 6.3--21.3)
  ----------------------------------------------------------------------------------------------

Lesion size {#sec014}
-----------

Mean lesion size for benign breast lesions was 11.54 mm (SD ± 5.16 mm) with a range from 4.9--21.7 mm. Malignant lesion had a mean lesion size of 12.54 mm (SD ± 4.03 mm) with a range of 6.3--21.3 mm without significant difference to the benign lesion (p = 0.18).

Diagnostic performance of apparent diffusion coefficient *D*~app~, fractional order calculus (FROC) derived parameters and intravoxel incoherent motion (IVIM) derived parameter {#sec015}
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*D*~app~ was significantly decreased (p\<0.001) in malignant lesions (median 0.97 μm^2^/ms; 25% - 75% percentile 0.87--1.01 μm^2^/ms) compared to benign lesions (1.20 μm^2^/ms; 1.06--1.47 μm^2^/ms) ([Fig 1](#pone.0176077.g001){ref-type="fig"}). Analysis of the Area Under the Curve (AUC) revealed an AUC of 0.89 (95% CI 0.79--0.974) for *D*~app~.

![Boxplots.\
Boxplots of the mean values for conventional apparent diffusion coefficient D~app~ (A) and fractional order calculus (FROC) model derived parameters D~FROC~ (B), β~FROC~ (C) and μ~FROC~ (D) for benign and malignant lesions. Vertical bars mark the range of the data excepting outliers, dots mark outliers, box marks 25^th^-- 75^th^ percentile, horizontal bar marks median.](pone.0176077.g001){#pone.0176077.g001}

Fractional Order Calculus (FROC) derived parameters *β*~FROC~ and *μ*~FROC~ revealed no statistically significant difference between malignant and benign lesions (for *β*~FROC~ p = 0.278, for *μ*~FROC~ p = 0.258) ([Fig 1](#pone.0176077.g001){ref-type="fig"}). In detail, *β*~FROC~ revealed a median of 0.69 (25%--75% percentile 0.60--0.77) for malignant and 0.75 (25%--75% percentile 0.64--0.78) for benign lesions. *μ*~FROC~ resulted in a mean of 8.34 μm (25%--75% percentile 7.74--9.05) for malignant and 8.91 μm (25%--75% percentile 7.30--10.30) for benign lesions. *D*~FROC~ revealed a significant difference between malignant and benign lesions with a *D*~FROC~ of 1.03 μm^2^/ms (25%--75% percentile 0.94--1.2) for malignant and 1.35 μm^2^/ms (25%--75% 1.14--1.51) for benign lesions (p = 0.003).

The AUC analysis revealed an AUC for *D*~app~ of 0.89 (95% CI 0.80--0.98) and for *D*~FROC~ of 0.75 (0.60--0.89). FROC parameter *β*~FROC~ showed an AUC of 0.59 (0.43--0.75) and *μ*~FROC~ revealed an AUC of 0.59 (0.42--0.77).

Individual comparison of the AUC curves revealed a significantly higher AUC of *D*~app~ compared to the FROC parameters *D*~FROC~ (area difference 0.14; p = 0.009), *β*~FROC~ (area difference 0.29; p = 0.003) and *μ*~FROC~ (area difference 0.29; p = 0.001) ([Fig 2](#pone.0176077.g002){ref-type="fig"}, image examples are shown in [Fig 3](#pone.0176077.g003){ref-type="fig"}).

![Receiving operator characteristics (ROC) curves.\
ROCs visualizing the diagnostic accuracy of the diffusion coefficient (D) and FROC derived parameters β~FROC~, μ~FROC~, and D~FROC~.](pone.0176077.g002){#pone.0176077.g002}

![Example of a breast cancer screening participant (66 years).\
Lesion with segmentation demonstrated as pink line. A) T2-weighted morphological sequence; B) diffusion weighted imaging (DWI, b = 1500 s/mm^2^); C) diffusion coefficient map D~app~ (scale given in μm^2^/ms); D) FROC diffusion coefficient map (scale given in μm^2^/ms); E) β~FROC~-map demonstrating a more heterogeneous signal; F) μ~FROC~-map demonstrating as well a relatively heterogeneous signal within the entire breast. Histopathology: invasive ductal carcinoma (IDC).](pone.0176077.g003){#pone.0176077.g003}

The IVIM parameter *D*~IVIM~ revealed an AUC of 0.91 (95% CI 0.82--0.99) and for *f*~IVIM~ and AUC of 0.54 (0.37--0.69) was found.

Evaluation of the size dependence of the AUC curves for the different parameters revealed a tendency for increasing AUC with larger sizes for *D*~app~, *D*~FROC~ and *μ*~FROC~. Dividing the lesions into groups larger or smaller than 10 mm revealed for lesions \>10 mm an AUC of *D*~app~ of 0.92 (95% CI 0.82--1.0) and for *D*~FROC~ of 0.81 (0.63--0.99). FROC parameter *β*~FROC~ showed an AUC of 0.59 (0.37--0.81) and *μ*~FROC~ revealed an AUC of 0.60 (0.35--0.86). For lesions smaller than 10 mm the AUC of *D*~app~ decreased to 0.86 (95% CI 0.61--1.0) and for *D*~FROC~ an AUC of 0.64 (0.32--0.96). FROC parameter *β*~FROC~ showed an AUC of 0.66 (0.38--0.93) and *μ*~FROC~ had an AUC of 0.52 (0.23--0.80).

A summary of the results is shown in [Table 3](#pone.0176077.t003){ref-type="table"}.

10.1371/journal.pone.0176077.t003

###### Area, 95% confidence interval and asymptotic significance of ROC curves.
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                                FROC parameters   apparent diffusion coefficient                
  ----------------------------- ----------------- -------------------------------- ------------ ------------
  **Area**                      0.75              0.59                             0.59         0.89
  **95% confidence interval**   0.60--0.89        0.43--0.75                       0.42--0.77   0.80--0.98
  **p value**                   p = 0.002         p = 0.27                         p = 0.25     p\<0.0001

Discussion {#sec016}
==========

Here we demonstrate that using the conventional apparent diffusion coefficient *D*~app~ in diffusion weighted breast imaging provides significantly different values between malignant and benign breast lesions. In contrast, out of the recently proposed FROC diffusion parameters *β*~FROC~, *μ*~FROC~ and *D*~FROC~, only the latter parameter revealed significant differences between malignant and benign lesions. The other parameters derived from the fractional order calculus model did not reliably differentiate between malignant and benign breast lesions detected in X-ray mammography. Comparing the different parameters, *D*~app~ resulted in a higher diagnostic accuracy in terms of AUC for predicting malignancy.

This is in concordance to existing literature and emphasizes the robust nature of the *D*~app~ for lesion characterization in the breast. Different studies have provided evidence that *D*~app~ values might help distinguish between malignant and benign breast lesions \[[@pone.0176077.ref014], [@pone.0176077.ref017]--[@pone.0176077.ref019]\]. However, in a similar manner as imaging features, *D*~app~ values show some overlap between malignant and benign lesions providing evidence for the necessity of further research. Common approaches to calculate the *D*~app~ values rely on monoexponential or biexponential models of diffusion within the imaged area/voxel \[[@pone.0176077.ref030]--[@pone.0176077.ref032]\]. However, potential intravoxel heterogeneity of the diffusion process might be underrepresented using these methods. A recently proposed new approach to estimate diffusions parameters suggested to take into account potential further diffusion derived parameters is the fractional order calculus model (FROC) \[[@pone.0176077.ref021]--[@pone.0176077.ref023]\]. Amongst those FROC parameters, *β*~FROC~ is a parameter recently described differentiating high- from low-grade glioblastomas by Sui et al. and described as mathematically equivalent to a heterogeneity measure described by Bennett et al. \[[@pone.0176077.ref021], [@pone.0176077.ref033]\]. Further parameters calculated with the FROC model are *μ*~FROC~ and *D*~FROC~. *μ*~FROC~ had previously been described as inferior in the grading of glioblastomas \[[@pone.0176077.ref021], [@pone.0176077.ref022]\].

The potential interdependence between *μ*~FROC~ and *D*~FROC~, which we consider as a limitation (see Supplemental Information: [S1 Text](#pone.0176077.s003){ref-type="supplementary-material"}: On the coupling of *D*~FROC~ and *μ*~FROC~; [S1 Fig](#pone.0176077.s001){ref-type="supplementary-material"}), might contribute to this fact as well as the fact that our study used a spectrum of b-values in the lower spectrum of previously described data \[[@pone.0176077.ref021]--[@pone.0176077.ref023]\] (see Supplemental Information: [S2 Text](#pone.0176077.s004){ref-type="supplementary-material"}: Choice of b-values;; [S2 Fig](#pone.0176077.s002){ref-type="supplementary-material"}). In addition, relevant general limitations of *μ*~FROC~ were already described by Zhou et al. since the calculation of *μ*~FROC~ becomes increasingly unstable regarding certain variations of *β*~FROC~ \[[@pone.0176077.ref021], [@pone.0176077.ref022]\].

In contrast to a previous study in brain tumors \[[@pone.0176077.ref021]\], FROC parameters did not perform as well as conventional apparent diffusion coefficient *D*~app~ in characterizing breast lesions. This might be related to the fact that the FROC parameter *β*~FROC~ is thought to be correlated to structural complexity \[[@pone.0176077.ref023]\]. Thus, there might be underlying biophysiological properties influencing the applicability of this complex FROC model in certain tissue components \[[@pone.0176077.ref021]--[@pone.0176077.ref023]\]. FROC parameters thus might be of dedicated value in differentiating changes within a more homogenous tissue such as the brain \[[@pone.0176077.ref021]\]. The breast tissue, especially in cases of fibrocystic changes and mastopathic tissue, already presents itself in a high structural complexity without interpreting the pure presence of structural complexity and microstructural heterogeneity as a dedicated index of malignancy. Within such a complex tissue structure, the standard apparent diffusion coefficient *D*~app~, as thought to be correlated to increasing cell density, might be of higher diagnostic value since allowing to detect and quantify abnormal cell conglomerates \[[@pone.0176077.ref014]\].

Although *β*~FROC~ is thought to be related to structural complexity \[[@pone.0176077.ref023]\], a straightforward link to the underlying microstructure is difficult to unveil. One difficulty is that *β*~FROC~ values smaller than one, which were found in our study and in other works (e.g. \[[@pone.0176077.ref021]--[@pone.0176077.ref023]\]), correspond to an initial slope of infinite magnitude of the signal damping with respect to *b* at *b* = 0. As this initial signal damping at *b* = 0 is commonly thought to reflect the apparent diffusion coefficient averaged over the medium \[[@pone.0176077.ref034]\], it becomes difficult to relate the FROC parameter *D*~FROC~ to *D*~app~. One might argue that this initial slope is masked by the intravoxel incoherent motion (IVIM) effect anyway \[[@pone.0176077.ref029]\]. But by suppressing the blood signal \[[@pone.0176077.ref035]\] or by using flow-compensated diffusion encodings \[[@pone.0176077.ref036], [@pone.0176077.ref037]\], the IVIM effect can be suppressed so that this loophole is not available in general. Presumably one must restrict oneself to b-values larger than a certain threshold when using the FROC model. Maybe multi-compartment distribution models might be useful to gain insights on appropriate thresholds \[[@pone.0176077.ref038], [@pone.0176077.ref039]\]. Although not primarily being the scope of this manuscript, future in depth investigation of IVIM parameters as previously described to be helpful for lesion characterization might further contribute to DWI analyses of the breast with *D*~IVIM~ providing a high AUC.

There are certain limitations to this study. First, we did not obtain as many and high b-values as used in the previously described studies \[[@pone.0176077.ref021]--[@pone.0176077.ref023]\]. This might have influence on the calculation of the parameters and limit the results and makes it impossible to assess the correct functional form of the signal damping preventing a validation of the appropriateness of the model for the applications to the data of our study. This aspect needs to be considered, since the diagnostic performance of our FROC parameters thus might both be an over- or underestimation of the diagnostic potential of the method. A second limitation is found in the relatively low number of study subjects for benign and malignant lesions, which is, however, in the range of other studies investigating novel fitting methods in diffusion weighted imaging. Further the correlation between the X-ray mammography as the primary descriptor of the lesion and the MR mammography was done visually without invasive markers, thus miscorrelations cannot be completely ruled out, however are considered minor due to the double consensus reading for lesion definition by two radiologists. Since the described breast lesions are assumedly smaller than the investigated brain lesions. Further, signal to noise (SNR) varied substantial between the FROC derived maps, which can have a bias on the accuracy and precision of derived parameters. Another limitation is that it has been reported that the diagnostic accuracy of quantitative DWI analyses might be influenced by lesion size, and the here reported lesions were rather small compared to literature \[[@pone.0176077.ref040]\].

In conclusion, to our knowledge, this is the first description of using an advanced FROC fitting model for diffusion weighted imaging of the breast. DWI derived FROC parameters *β*~FROC~ and *μ*~FROC~ did not show a significant improvement in differentiating between malignant and benign breast lesions compared to apparent diffusion coefficient *D*~app~, which might be related to the structural heterogeneity of breast tissue or to the maximal b-value used.
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